RCEL Stock Forecast & Price Target

AVITA Medical is viewed favorably because its RECELL system addresses a clear clinical pain point by enabling spray-on skin from a small sample in about 30 minutes, reducing graft dependence while serving adult and paediatric burn and soft-tissue reconstruction patients. Its US-focused strategy appears to be paying off, with use in most of the 140 US burn centers, total US RECELL volume rising about 11% sequentially in 2Q26 to over 2,600 units, and all seven MACs publishing payment rates, which should support more predictable adoption. The investment case is further strengthened by portfolio expansion and diversification: PermeaDerm’s randomized study showed a 70% product-cost advantage versus allograft, a 95.7% reduction in preparation time, comparable outcomes, and management guided FY26 revenue of $86M to $89M while targeting cash flow break-even in 4Q26.

AVITA Medical is vulnerable to concentration risk because it remains largely a single-product company, with RECELL carrying most of the commercial story despite its innovation in spray-on skin and use across most of the 140 US burn centers. The business also faces fundamental execution risk from inconsistent adoption in full-thickness skin defects and burns, limited capital, and persistent reimbursement issues from third-party payers, while active commercialization remains focused on the US rather than approved markets such as Australia, Canada, and China. Although international sales, particularly in Japan, are growing, the valuation still depends on sustained top-line growth and favorable clinical and regulatory timing, leaving the company exposed if adoption or reimbursement momentum slows.